Table 1 Baseline characteristics of 155 AS patients according to the three WHO BMI categories
From: Body mass index influences the response to infliximab in ankylosing spondylitis
Whole AS population (n= 155) | BMI < 25 kg/m2 (n= 63) | BMI [25-30] kg/m2 (n= 54) | BMI > 30 kg/m2 (n= 38) | Pvalue | |
|---|---|---|---|---|---|
Age (years), median [IQR] | 43.1 [35.0-51.8] | 38.5 [31.6-48.6] | 45.0 [35.6-52.6] | 45.4 [40.0-50.0] | 0.0127 |
Male gender, n (%) | 98 (63.3) | 45 (71.4) | 36 (66.6) | 17 (44.7) | 0.0214 |
HLAB27, n (%) | 96 (64.9) | 48 (76.2) | 28 (57.1) | 20 (55.6) | 0.0451 |
Disease duration (years), median [IQR] | 8.0 [3.0-12.0] | 8.0 [4.0-12.0] | 7.0 [3.0-11.0] | 6.0 [3.0-12.0] | 0.7640 |
BASDAI (0 to -100 mm), median [IQR] | 60.0 [47.5-70.0] | 60.0 [50.0-73.0] | 56.0 [48.0-66.0] | 62.0 [34.0-70.0] | 0.4782 |
VAS pain (0 to 100 mm), median [IQR] | 61.0 [50.0-75.0] | 65.0 [50.0-80.0] | 60.0 [50.0-70.0] | 70.0 [49.0-75.0] | 0.4598 |
Use of NSAIDs (% of maximal dose), mean (SD) | 62.2 (45.7) | 72.2 (42.9) | 53.7 (42.9) | 57.4 (46.0) | 0.0703 |
CRP (mg/dl), median [IQR] | 10.0 [5.0-24.0] | 11.0 [5.0-23.0] | 14.0 [5.0-33.0] | 7.9 [5.0-16.0] | 0.2550 |